The University of Texas MD Anderson Cancer Center is conducting parallel research on a universal vaccine against pancreatic ...

About 90% of pancreatic cancer cases include a mutation called KRAS, meaning nonpersonalized vaccines, which could be ...

KRAS G12C inhibitors mark a breakthrough in oncology, but resistance is driving the need for smarter preclinical models and ...

Researchers at Hopkins have made strides in pancreatic cancer research, both in understanding age-related differences in ...

with KRAS G12C mutations, as “comprehensive data for this medicine [was] not yet available.” Mirati – which already has FDA approval for Krazati for this indication – said it disagrees ...

A new analysis of data from the KeyNote-042 trial in previously-untreated NSCLC has shown that the drug is effective regardless of whether a patient’s tumour bears KRAS mutations – which make ...

state of greater than 90% of all KRAS mutations and to provide complete target coverage in tumors. These properties have the potential to translate into best-in-class safety and efficacy.

RAS is the most frequently mutated oncogene in cancer, with KRAS mutations occurring in nearly one-quarter of all human cancers. RAS mutations impair the ability of RAS to convert from its active ...

RAS is the most frequently mutated oncogene in cancer, with KRAS mutations occurring in nearly one-quarter of all human cancers. RAS mutations impair the ability of RAS to convert from its active ...